As we all know, there are many differences between gilts and adult sows, and their performance is: (1) Health is not as stable as adult sows; (2) Problems are likely to occur during the first delivery; (3) The thickness of its backfat and its contact with the boar must be taken into consideration in production; (4) The interval from weaning to breeding is generally longer, which can easily lead to the problem of normal operation of breeding and gestation housing; (5) Low immunity results in low resistance of their offspring, which was confirmed in early weaning (SEW) isolation and was also indirectly confirmed by Danish asthma elimination process. In view of the above reasons, in order to enable gilts to play the greatest role in the subsequent production, sows are fed on a sub-breeding basis. The production process of sows divided by parity is as follows: In 1991, R. Robitaille, a pig farm manager in Quebec, Canada, told his consulting vet Camille Moore (a famous pig and swine disease expert in Canada) that he planned to move the gilts to another site for breeding, and then put the pregnancy 50 The sow, who was ~70 days old, then led to his own farm, when Camille Moore strongly disapproved. However, by 1995, it has been found through four years of practice that this method has been very successful. Traditional approach: Reserve pigs are only pregnant and do not produce first-born pigs as replacement pigs instead of old sows. Divided at the time of birth: gilts not only over-produced the first child, but also matched with the species 50 to 70 days later, into the old sow group. In addition, piglets born to the first-born sow and piglets born to more than two-sisters were kept separately. Ibrutinib is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK) that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma.
Ibrutinib Intermediates,Cas 330786-24-8,Cas 143900-44-1,High Purity Ibrutinib Intermediates Nanjing Sunshine Biotech Co., Ltd , http://www.sunshine-bio.com
Ibrutinib is used to treat chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, and marginal zone lymphoma.
We produce a series of complete intermediates for Ibrutinib, intermediate I (CAS No. 330786-24-8) and intermediate II (CAS No. 143900-44-1) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
The gilts are reared separately and differ from the adult sows